Toll-like receptor 7 regulates osteoclastogenesis in rheumatoid arthritis

• Published in: Journal of biochemistry (Tokyo) 2019-09, Vol.166 (3), p.259-270
• Main Authors: Kim, Kyoung-Woon, Kim, Bo-Mi, Won, Ji-Yeon, Lee, Kyung-Ann, Kim, Hae-Rim, Lee, Sang-Heon
• Format: Article
• Language: English
• Subjects: Aged; Arthritis, Rheumatoid - metabolism; Arthritis, Rheumatoid - pathology; Cells, Cultured; Female; Fibroblasts - metabolism; Fibroblasts - pathology; Humans; Male; Middle Aged; Osteogenesis; Toll-Like Receptor 7 - metabolism
• ISSN: 0021-924X; 1756-2651
• DOI: 10.1093/jb/mvz033

This study aimed to determine the regulatory role of toll-like receptor 7 (TLR7) in receptor activator of nuclear factor kappa-B ligand (RANKL) production and osteoclast differentiation in rheumatoid arthritis (RA). In confocal microscopy, the co-expression of TLR7, CD55 and RANKL was determined in RA synovial fibroblasts. After RA synovial fibroblasts were treated with imiquimod, the RANKL gene expression and protein production were determined by real-time polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA). Osteoclastogenesis from peripheral blood CD14+ monocytes which were cultured with imiquimod was assessed by determining the numbers of tartrate-resistant acid phosphatase (TRAP)-positive multinucleated cells. The signal pathways mediating the TLR7-induced RANKL expression and osteoclastogenesis were analysed after inhibition of intracellular signal molecules and their phosphorylation. Imiquimod stimulated the expression of TLR7 and RANKL and production of RANKL in RA synovial fibroblasts, increasing the phosphorylation of TRAF6, IRF7, mitogen-activated protein kinases (MAPK), c-Jun and NFATc1. When CD14+ monocytes were cultured with imiquimod or co-cultured with imiquimod-pre-treated RA synovial fibroblasts, they were differentiated into TRAP+ multinucleated osteoclasts in the absence of RANKL. TLR7 activation-induced osteoclastogenesis in RA through direct induction of osteoclast differentiation from its precursors and up-regulation of RANKL production in RA synovial fibroblasts. Thus, the blockage of TLR7 pathway could be a promising therapeutic strategy for preventing bone destruction in RA.